Vector Science & Therapeutics and Caresyntax Announce

Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of...

- Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative registry across a network of partner surgical facilities. - The program will compare postoperative outcomes (opioid utilization, length of stay, and patient-reported pain) between standard of care and procedures using VectorMist and The LASSO Protocol. - The parties have agreed to explore extending the same evidence architecture across Vector's broader portfolio, including its peptide therapeutics programs, subject to a separate agreement.

MEQUON, Wis. and SAN FRANCISCO, July 17, 2026 /CNW/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) ("Vector") and Caresyntax, a global leader in surgical intelligence and real-world evidence, today announced a strategic partnership to build the clinical evidence infrastructure supporting VectorMistTM, Vector's localized atomized drug delivery platform, and The LASSO ProtocolTM (Laparoscopic Atomization System for Sparing Opioids). VectorMist is designed to deliver atomized medication directly to the surgical site during laparoscopic procedures, providing targeted pain control at the

Source and reference

source and reducing reliance on systemic opioids in postoperative recovery. The LASSO Protocol is the clinical protocol built on the VectorMist platform. Under the agreement, Caresyntax will design and operate a multi-phase real-world evidence program across a network of partner surgical facilities. The program begins with baseline data collection on current standard-of-care procedures, capturing postoperative opioid utilization, length of stay, and patient-reported pain scores. A comparative phase then measures outcomes from VectorMist procedures against that baseline. The program culminates in a prospective comparative registry across the participating surgical network, giving institutions the ability to benchmark their outcomes against peer and cohort performance on a standardized data model. The partnership positions VectorMist as a data-enabled surgical platform rather than a...

Read original source

Why this matters locally

This business story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.

Local impact

BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.

Timeline